Related Experiment Video
Updated: Jun 3, 2026

Automating Tumor Implantation in Zebrafish Larvae for Cancer Research and Medicine
Published on: September 19, 2025
Interview with Jürg Zimmermann, global head of oncology & exploratory chemistry at Novartis
1Novartis Pharma AG, Postfach, Basel, Switzerland. juerg.zimmermann@novartis.com
Abstract:
Dr Jürg Zimmermann is the inventor of the drug imatinib (Gleevec(®), Glivec(®)), which entered the market in 2001 and revolutionized the treatment of chronic myelogenous leukemia. He talks to Future Medicinal Chemistry about his career as a medicinal chemist, current issues in pharmaceutical R&D and his experiences of developing Gleevec, the first protein kinase to get onto market.
Related Concept Videos
Tumor Immunotherapy
Treatment Resistent Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

